Contact
searchSearch
HMP Global
Login

Myelodysplastic Syndrome Specialty Channel

Myelodysplastic Syndrome
Specialty Channel
FDA Approval
FDA Approves Treosulfan With Fludarabine for Patients With AML or MDS Prior to AlloHSCT
02/07/2025
Emily Estrada
On January 21, 2025, the FDA approved treosulfan with fludarabine prior to allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome.
On January 21, 2025, the FDA approved treosulfan with fludarabine prior to allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome.
On January 21, 2025, the FDA...
02/07/2025
Oncology
Benjamin Rolles, MD
Conference Coverage
Impact of Treatment Response to Hypomethylating Agents and Time-to-Transplant Status on Outcomes Among Patients With MDS
01/13/2025
Time to alloHCT may be more impactful than treatment response to hypomethylating agent-based therapy on outcomes for patients with myelodysplastic syndromes, according to research presented by Benjamin Rolles at the 66th ASH Annual Meeting.
Time to alloHCT may be more impactful than treatment response to hypomethylating agent-based therapy on outcomes for patients with myelodysplastic syndromes, according to research presented by Benjamin Rolles at the 66th ASH Annual Meeting.
Time to alloHCT may be more...
01/13/2025
Oncology
News
FDA Approves Oral Formulation of Imatinib for Patients With Certain Leukemias and Gastrointestinal Tumors
11/25/2024
Stephanie Holland
The FDA has approved an advanced liquid formulation of imatinib for patients with certain leukemias and gastrointestinal tumors to increase dosing accuracy.
The FDA has approved an advanced liquid formulation of imatinib for patients with certain leukemias and gastrointestinal tumors to increase dosing accuracy.
The FDA has approved an advanced...
11/25/2024
Oncology
News
Luspatercept as Novel Standard of Care for ESA-Naive Patients With Transfusion-Dependent, Lower-Risk MDS
10/02/2024
Amber Denham
Luspatercept provides a new standard of care for erythropoiesis-stimulating agent-naïve patients with transfusion-dependent, lower-risk myelodysplastic syndromes, determined primary analysis results from the phase 3 COMMANDS study.
Luspatercept provides a new standard of care for erythropoiesis-stimulating agent-naïve patients with transfusion-dependent, lower-risk myelodysplastic syndromes, determined primary analysis results from the phase 3 COMMANDS study.
Luspatercept provides a new...
10/02/2024
Oncology
News
Initial Low Dose Lenalidomide Over 2 Years Improves Treatment Response Among Non-Transfusion-Dependent Patients With Low-Risk MDS
09/19/2024
Amber Denham
An initial treatment of low doses of lenalidomide distributed across 2 years was shown to safely prolong the time to transfusion-dependency and improve responses among non-transfusion-dependent patients with low-risk, del(5q) myelodysplastic...
An initial treatment of low doses of lenalidomide distributed across 2 years was shown to safely prolong the time to transfusion-dependency and improve responses among non-transfusion-dependent patients with low-risk, del(5q) myelodysplastic...
An initial treatment of low...
09/19/2024
Oncology
News
FDA Grants Approval to Imetelstat for Patients With Low to Intermediate-1 Risk Myelodysplastic Syndrome With Transfusion-Dependent Anemia
06/21/2024
The FDA granted approval to imetelstat for patients with low to intermediate-1 risk MDS with transfusion-dependent anemia requiring 4 or more red blood cell transfusion units over 8 weeks, who cannot derive benefit from...
The FDA granted approval to imetelstat for patients with low to intermediate-1 risk MDS with transfusion-dependent anemia requiring 4 or more red blood cell transfusion units over 8 weeks, who cannot derive benefit from...
The FDA granted approval to...
06/21/2024
Oncology
Quiz
Safety of Oral Decitabine Cedazuridine vs Intravenous Decitabine for Patients With MDS or CML
06/02/2024
06/02/2024
Oncology
News
Azacitidine Maintenance Demonstrates Lower Disease Progression Rate Among Patients With High-Risk FLT3-Negative AML/MDS
03/05/2024

Amber Denham

Amber Denham
According to a retrospective analysis, azacitidine maintenance is associated with a lower progression rate in patients with high-risk FLT3-negative acute myeloid leukemia or myelodysplastic syndrome.
According to a retrospective analysis, azacitidine maintenance is associated with a lower progression rate in patients with high-risk FLT3-negative acute myeloid leukemia or myelodysplastic syndrome.
According to a retrospective...
03/05/2024
Oncology
News
Oral Decitabine Cedazuridine Safe, Effective Alternative to Intravenous Decitabine for Patients With MDS or CML
02/21/2024
Amber Denham
Oral decitabine cedazuridine demonstrates safety and efficacy as an alternative to intravenous decitabine treatment among patients with myelodysplastic syndromes or chronic myelomonocytic leukemia, according to phase 3 study results.
Oral decitabine cedazuridine demonstrates safety and efficacy as an alternative to intravenous decitabine treatment among patients with myelodysplastic syndromes or chronic myelomonocytic leukemia, according to phase 3 study results.
Oral decitabine cedazuridine...
02/21/2024
Oncology
News
Assessment of Individualized MRD With NGS, ddPCR Effective for Early Detection of MDS Relapse
02/09/2024
Amber Denham
Evaluating individualized measurable residual disease with next-generation sequencing and droplet digital polymerase chain reaction is feasible and can be used for early detection of relapse among patients with myelodysplastic syndrome,...
Evaluating individualized measurable residual disease with next-generation sequencing and droplet digital polymerase chain reaction is feasible and can be used for early detection of relapse among patients with myelodysplastic syndrome,...
Evaluating individualized...
02/09/2024
Oncology
News
Efficacy of Azacitidine Among Treatment-Naive Patients With Higher-Risk Myelodysplastic Syndromes
01/31/2024
Amber Denham
Azacitidine demonstrated low complete remission rates and low median overall survival as a frontline therapy for patients with high-risk myelodysplastic syndromes, according to a retrospective study.
Azacitidine demonstrated low complete remission rates and low median overall survival as a frontline therapy for patients with high-risk myelodysplastic syndromes, according to a retrospective study.
Azacitidine demonstrated low...
01/31/2024
Oncology

News

FDA Approval
FDA Approves Treosulfan With Fludarabine for Patients With AML or MDS Prior to AlloHSCT
02/07/2025
Emily Estrada
On January 21, 2025, the FDA approved treosulfan with fludarabine prior to allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome.
On January 21, 2025, the FDA approved treosulfan with fludarabine prior to allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome.
On January 21, 2025, the FDA...
02/07/2025
Oncology
Benjamin Rolles, MD
Conference Coverage
Impact of Treatment Response to Hypomethylating Agents and Time-to-Transplant Status on Outcomes Among Patients With MDS
01/13/2025
Time to alloHCT may be more impactful than treatment response to hypomethylating agent-based therapy on outcomes for patients with myelodysplastic syndromes, according to research presented by Benjamin Rolles at the 66th ASH Annual Meeting.
Time to alloHCT may be more impactful than treatment response to hypomethylating agent-based therapy on outcomes for patients with myelodysplastic syndromes, according to research presented by Benjamin Rolles at the 66th ASH Annual Meeting.
Time to alloHCT may be more...
01/13/2025
Oncology
News
FDA Approves Oral Formulation of Imatinib for Patients With Certain Leukemias and Gastrointestinal Tumors
11/25/2024
Stephanie Holland
The FDA has approved an advanced liquid formulation of imatinib for patients with certain leukemias and gastrointestinal tumors to increase dosing accuracy.
The FDA has approved an advanced liquid formulation of imatinib for patients with certain leukemias and gastrointestinal tumors to increase dosing accuracy.
The FDA has approved an advanced...
11/25/2024
Oncology
News
Luspatercept as Novel Standard of Care for ESA-Naive Patients With Transfusion-Dependent, Lower-Risk MDS
10/02/2024
Amber Denham
Luspatercept provides a new standard of care for erythropoiesis-stimulating agent-naïve patients with transfusion-dependent, lower-risk myelodysplastic syndromes, determined primary analysis results from the phase 3 COMMANDS study.
Luspatercept provides a new standard of care for erythropoiesis-stimulating agent-naïve patients with transfusion-dependent, lower-risk myelodysplastic syndromes, determined primary analysis results from the phase 3 COMMANDS study.
Luspatercept provides a new...
10/02/2024
Oncology
News
Initial Low Dose Lenalidomide Over 2 Years Improves Treatment Response Among Non-Transfusion-Dependent Patients With Low-Risk MDS
09/19/2024
Amber Denham
An initial treatment of low doses of lenalidomide distributed across 2 years was shown to safely prolong the time to transfusion-dependency and improve responses among non-transfusion-dependent patients with low-risk, del(5q) myelodysplastic...
An initial treatment of low doses of lenalidomide distributed across 2 years was shown to safely prolong the time to transfusion-dependency and improve responses among non-transfusion-dependent patients with low-risk, del(5q) myelodysplastic...
An initial treatment of low...
09/19/2024
Oncology
News
FDA Grants Approval to Imetelstat for Patients With Low to Intermediate-1 Risk Myelodysplastic Syndrome With Transfusion-Dependent Anemia
06/21/2024
The FDA granted approval to imetelstat for patients with low to intermediate-1 risk MDS with transfusion-dependent anemia requiring 4 or more red blood cell transfusion units over 8 weeks, who cannot derive benefit from...
The FDA granted approval to imetelstat for patients with low to intermediate-1 risk MDS with transfusion-dependent anemia requiring 4 or more red blood cell transfusion units over 8 weeks, who cannot derive benefit from...
The FDA granted approval to...
06/21/2024
Oncology
News
Azacitidine Maintenance Demonstrates Lower Disease Progression Rate Among Patients With High-Risk FLT3-Negative AML/MDS
03/05/2024

Amber Denham

Amber Denham
According to a retrospective analysis, azacitidine maintenance is associated with a lower progression rate in patients with high-risk FLT3-negative acute myeloid leukemia or myelodysplastic syndrome.
According to a retrospective analysis, azacitidine maintenance is associated with a lower progression rate in patients with high-risk FLT3-negative acute myeloid leukemia or myelodysplastic syndrome.
According to a retrospective...
03/05/2024
Oncology
News
Oral Decitabine Cedazuridine Safe, Effective Alternative to Intravenous Decitabine for Patients With MDS or CML
02/21/2024
Amber Denham
Oral decitabine cedazuridine demonstrates safety and efficacy as an alternative to intravenous decitabine treatment among patients with myelodysplastic syndromes or chronic myelomonocytic leukemia, according to phase 3 study results.
Oral decitabine cedazuridine demonstrates safety and efficacy as an alternative to intravenous decitabine treatment among patients with myelodysplastic syndromes or chronic myelomonocytic leukemia, according to phase 3 study results.
Oral decitabine cedazuridine...
02/21/2024
Oncology
News
Assessment of Individualized MRD With NGS, ddPCR Effective for Early Detection of MDS Relapse
02/09/2024
Amber Denham
Evaluating individualized measurable residual disease with next-generation sequencing and droplet digital polymerase chain reaction is feasible and can be used for early detection of relapse among patients with myelodysplastic syndrome,...
Evaluating individualized measurable residual disease with next-generation sequencing and droplet digital polymerase chain reaction is feasible and can be used for early detection of relapse among patients with myelodysplastic syndrome,...
Evaluating individualized...
02/09/2024
Oncology
News
Efficacy of Azacitidine Among Treatment-Naive Patients With Higher-Risk Myelodysplastic Syndromes
01/31/2024
Amber Denham
Azacitidine demonstrated low complete remission rates and low median overall survival as a frontline therapy for patients with high-risk myelodysplastic syndromes, according to a retrospective study.
Azacitidine demonstrated low complete remission rates and low median overall survival as a frontline therapy for patients with high-risk myelodysplastic syndromes, according to a retrospective study.
Azacitidine demonstrated low...
01/31/2024
Oncology
News
Sintilimab Plus Anlotinib Demonstrates Promise in Relapsed/Refractory Small Cell Lung Cancer
04/02/2026
Stephanie Holland
Results from a phase 2 trial suggest that sintilimab plus anlotinib demonstrates encouraging efficacy with manageable safety among patients with relapsed/refractory small cell lung cancer (SCLC) who have a short chemotherapy-free...
Results from a phase 2 trial suggest that sintilimab plus anlotinib demonstrates encouraging efficacy with manageable safety among patients with relapsed/refractory small cell lung cancer (SCLC) who have a short chemotherapy-free...
Results from a phase 2 trial...
04/02/2026
Oncology
News
Adebrelimab Plus Chemotherapy Maintains Long-Term Survival Benefit in ES-SCLC
04/02/2026
Stephanie Holland
Updated results from the phase 3 CAPSTONE-1 trial demonstrate that adebrelimab plus chemotherapy continues to provide durable survival benefit in patients with extensive-stage small cell lung cancer.
Updated results from the phase 3 CAPSTONE-1 trial demonstrate that adebrelimab plus chemotherapy continues to provide durable survival benefit in patients with extensive-stage small cell lung cancer.
Updated results from the phase 3...
04/02/2026
Oncology
News
Lurbinectedin Plus Atezolizumab Delays Subsequent Therapy and Maintains Survival Benefit in ES-SCLC
04/02/2026
Stephanie Holland
Exploratory results from the phase 3 IMforte trial suggest that first-line treatment with lurbinectedin plus atezolizumab delays subsequent therapy and maintains overall survival benefit in patients with extensive-stage small cell lung cancer.
Exploratory results from the phase 3 IMforte trial suggest that first-line treatment with lurbinectedin plus atezolizumab delays subsequent therapy and maintains overall survival benefit in patients with extensive-stage small cell lung cancer.
Exploratory results from the...
04/02/2026
Oncology
FDA Approval
FDA Approves Brexucabtagene Autoleucel for R/R Mantle Cell Lymphoma
04/02/2026
Stephanie Holland
Based on results from the phase 2 ZUMA-2 study, the FDA approved brexucabtagene autoleucel for adult patients with relapsed/refractory mantle cell lymphoma, including those who are BTK inhibitor–naïve.
Based on results from the phase 2 ZUMA-2 study, the FDA approved brexucabtagene autoleucel for adult patients with relapsed/refractory mantle cell lymphoma, including those who are BTK inhibitor–naïve.
Based on results from the phase...
04/02/2026
Oncology
News
Consolidation Serplulimab Following Hypo-cCRT Improves Outcomes in Limited-Stage Small Cell Lung Cancer
04/02/2026
Emily Estrada
Updated results from the phase 2 ASTRUM-LC01 trial demonstrate that following concurrent Hypo-cCRT with consolidation serplulimab improves survival with manageable safety in limited-stage small cell lung cancer.
Updated results from the phase 2 ASTRUM-LC01 trial demonstrate that following concurrent Hypo-cCRT with consolidation serplulimab improves survival with manageable safety in limited-stage small cell lung cancer.
Updated results from the phase 2...
04/02/2026
Oncology
News
Izalontamab Brengitecan Plus Serplulimab Demonstrates Strong Promise in Treatment-Naïve ES-SCLC
04/01/2026
Emily Estrada
According to results from the phase 2 BL-B01D1-204-01 study, izalontamab brengitecan plus serplulimab demonstrated encouraging efficacy with manageable safety in treatment- extensive-stage small cell lung cancer.
According to results from the phase 2 BL-B01D1-204-01 study, izalontamab brengitecan plus serplulimab demonstrated encouraging efficacy with manageable safety in treatment- extensive-stage small cell lung cancer.
According to results from the...
04/01/2026
Oncology
News
Transdermal Estradiol Noninferior to LHRH Agonists in Locally Advanced Prostate Cancer
04/01/2026
Stephanie Holland
Results from a phase 3 study demonstrated that transdermal estradiol was noninferior to luteinizing hormone-releasing hormone agonists for survival outcomes among patients with locally advanced prostate cancer.
Results from a phase 3 study demonstrated that transdermal estradiol was noninferior to luteinizing hormone-releasing hormone agonists for survival outcomes among patients with locally advanced prostate cancer.
Results from a phase 3 study...
04/01/2026
Oncology
News
Etrumadenant-Based Chemoimmunotherapy Improves Survival in Metastatic Colorectal Cancer
04/01/2026
Emily Estrada
Results from the phase 2 ARC-9 study, demonstrate that etrumadenant plus zimberelimab, mFOLFOX-6, and bevacizumab significantly improves survival in heavily pretreated patients with metastatic colorectal cancer.
Results from the phase 2 ARC-9 study, demonstrate that etrumadenant plus zimberelimab, mFOLFOX-6, and bevacizumab significantly improves survival in heavily pretreated patients with metastatic colorectal cancer.
Results from the phase 2 ARC-9...
04/01/2026
Oncology
News
Distinct Immune Microenvironment Associated With Long-Term Survival in High-Grade Glioma
03/31/2026
Emily Estrada
Results from a translational analysis suggest that long-term survival in patients with high-grade glioma is associated with a distinct immune microenvironment characterized by enhanced NK cell activity and microglial activation.
Results from a translational analysis suggest that long-term survival in patients with high-grade glioma is associated with a distinct immune microenvironment characterized by enhanced NK cell activity and microglial activation.
Results from a translational...
03/31/2026
Oncology
Jeffrey Lancet, MD
Videos
Optimizing Decision-Making on Transplantation for Patients With AML
03/31/2026
Jeffrey Lancet, MD
At the 2026 LL&M Winter Symposium, Jeffrey Lancet, MD, discussed the latest clinical insights into determining which patients with acute myeloid leukemia should be recommended for transplant.
At the 2026 LL&M Winter Symposium, Jeffrey Lancet, MD, discussed the latest clinical insights into determining which patients with acute myeloid leukemia should be recommended for transplant.
At the 2026 LL&M Winter...
03/31/2026
Oncology

Interactive Features

Quiz
Safety of Oral Decitabine Cedazuridine vs Intravenous Decitabine for Patients With MDS or CML
06/02/2024
06/02/2024
Oncology
Quiz
Eltrombopag for Low-Risk Myelodysplastic Syndromes and Severe Thrombocytopenia
01/05/2024
True or False: Results from the phase 2 EQOL-MDS trial indicated that patients who received eltrombopag demonstrated a higher platelet response and less frequent significant bleeding compared to patients who received a placebo.
True or False: Results from the phase 2 EQOL-MDS trial indicated that patients who received eltrombopag demonstrated a higher platelet response and less frequent significant bleeding compared to patients who received a placebo.
True or False: Results from the...
01/05/2024
Oncology
Quiz
Haploidentical Donors vs Matched Unrelated Donors for High-Risk MDS
06/09/2023
True or False: In a retrospective multicenter study on the use of haploidentical donors for treatment of high-risk MDS, results indicated that overall survival and progression-free survival were significantly higher among patients who...
True or False: In a retrospective multicenter study on the use of haploidentical donors for treatment of high-risk MDS, results indicated that overall survival and progression-free survival were significantly higher among patients who...
True or False: In a...
06/09/2023
Oncology
Quiz
Quiz: Post-Transplant Eprenetapopt and Azacitidine Maintenance in TP53-Mutant AML and MDS
10/05/2022
True or False: In a recent phase 2 trial, post-transplant eprenetapopt and azacitidine maintenance demonstrated promising safety and efficacy in TP53-mutant acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
True or False: In a recent phase 2 trial, post-transplant eprenetapopt and azacitidine maintenance demonstrated promising safety and efficacy in TP53-mutant acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
True or False: In a recent phase...
10/05/2022
Oncology
Quiz
Sequential Thoracic Radiotherapy After Chemoimmunotherapy in ES-SCLC
04/02/2026
In patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy, which thoracic radiotherapy strategy was associated with improved survival outcomes?
In patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy, which thoracic radiotherapy strategy was associated with improved survival outcomes?
In patients with extensive-stage...
04/02/2026
Oncology
Quiz
Zanzalintinib Plus Atezolizumab in Relapsed/Refractory Metastatic Colorectal Cancer
04/01/2026
Emily Estrada
True or False: Results from the STELLAR-303 trial demonstrate that zanzalintinib plus atezolizumab does not significantly improve overall survival compared with regorafenib in patients with relapsed/refractory metastatic colorectal cancer...
True or False: Results from the STELLAR-303 trial demonstrate that zanzalintinib plus atezolizumab does not significantly improve overall survival compared with regorafenib in patients with relapsed/refractory metastatic colorectal cancer...
True or False: Results from the...
04/01/2026
Oncology
Quiz
Auceliciclib for Advanced Solid Tumors and Recurrent High-Grade Glioma
03/31/2026
Did auceliciclib demonstrate acceptable tolerability and preliminary signs of clinical activity in patients with advanced solid tumors and recurrent/relapsed high-grade glioma?
Did auceliciclib demonstrate acceptable tolerability and preliminary signs of clinical activity in patients with advanced solid tumors and recurrent/relapsed high-grade glioma?
Did auceliciclib demonstrate...
03/31/2026
Oncology
Quiz
Tucatinib Plus Trastuzumab for HER2-Posititive Metastatic Colorectal Cancer
03/18/2026
Test your knowledge of the clinical benefit of tucatinib plus trastuzumab therapy in patients with chemotherapy-refractory, HER2-positive, RAS wild-type metastatic colorectal cancer.
Test your knowledge of the clinical benefit of tucatinib plus trastuzumab therapy in patients with chemotherapy-refractory, HER2-positive, RAS wild-type metastatic colorectal cancer.
Test your knowledge of the...
03/18/2026
Oncology
Quiz
Serum LDH and α-HBDH Levels in SCLC
03/04/2026
Test your knowledge of how serum LDH and α-HBDH levels following first-line chemoimmunotherapy may influence survival outcomes in extensive-stage small cell lung cancer (ES-SCLC).
Test your knowledge of how serum LDH and α-HBDH levels following first-line chemoimmunotherapy may influence survival outcomes in extensive-stage small cell lung cancer (ES-SCLC).
Test your knowledge of how serum...
03/04/2026
Oncology
Quiz
Predictive Accuracy of Whole-Brain Radiotherapy Response in SCLC With Brain Metastases
03/03/2026
Test your knowledge on a multi-omics model for predicting responses to whole-brain radiotherapy among patents with small cell lung cancer.
Test your knowledge on a multi-omics model for predicting responses to whole-brain radiotherapy among patents with small cell lung cancer.
Test your knowledge on a...
03/03/2026
Oncology
Quiz
Safusidenib Erbumine for IDH1-Mutated Glioma
03/03/2026
Test your knowledge on safusidenib erbumine, a selective mutant IDH1 inhibitor, patients with newly diagnosed, chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutated gliomas.
Test your knowledge on safusidenib erbumine, a selective mutant IDH1 inhibitor, patients with newly diagnosed, chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutated gliomas.
Test your knowledge on...
03/03/2026
Oncology
Quiz
Venetoclax Plus CACAG Therapy for Relapsed/Refractory Acute Myeloid Leukemia
03/02/2026
Test your knowledge on the response rates and survival outcomes of chidamide, azacitidine, cytarabine, aclarubicin, G-CSF (CACAG), and venetoclax therapy for patients with R/R acute myeloid leukemia.
Test your knowledge on the response rates and survival outcomes of chidamide, azacitidine, cytarabine, aclarubicin, G-CSF (CACAG), and venetoclax therapy for patients with R/R acute myeloid leukemia.
Test your knowledge on the...
03/02/2026
Oncology
Quiz
Oral Iberdomide Combination for R/R MM
02/24/2026
Test your knowledge on the safety profile of oral iberdomide plus low-dose cyclophosphamide and dexamethasone for patents with R/R multiple myeloma.
Test your knowledge on the safety profile of oral iberdomide plus low-dose cyclophosphamide and dexamethasone for patents with R/R multiple myeloma.
Test your knowledge on the...
02/24/2026
Oncology
Quiz
High-Risk Stratification in Cutaneous Squamous Cell Carcinoma
02/19/2026
Test your knowledge of results from the phase 3 TROG 05.01 trial evaluating postoperative radiotherapy with or without concurrent chemotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck.
Test your knowledge of results from the phase 3 TROG 05.01 trial evaluating postoperative radiotherapy with or without concurrent chemotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck.
Test your knowledge of results...
02/19/2026
Oncology

Recent News

FDA Approval
FDA Approves Treosulfan With Fludarabine for Patients With AML or MDS Prior to AlloHSCT
02/07/2025
Emily Estrada
On January 21, 2025, the FDA approved treosulfan with fludarabine prior to allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome.
On January 21, 2025, the FDA approved treosulfan with fludarabine prior to allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome.
On January 21, 2025, the FDA...
02/07/2025
Oncology
News
FDA Approves Oral Formulation of Imatinib for Patients With Certain Leukemias and Gastrointestinal Tumors
11/25/2024
Stephanie Holland
The FDA has approved an advanced liquid formulation of imatinib for patients with certain leukemias and gastrointestinal tumors to increase dosing accuracy.
The FDA has approved an advanced liquid formulation of imatinib for patients with certain leukemias and gastrointestinal tumors to increase dosing accuracy.
The FDA has approved an advanced...
11/25/2024
Oncology
News
Luspatercept as Novel Standard of Care for ESA-Naive Patients With Transfusion-Dependent, Lower-Risk MDS
10/02/2024
Amber Denham
Luspatercept provides a new standard of care for erythropoiesis-stimulating agent-naïve patients with transfusion-dependent, lower-risk myelodysplastic syndromes, determined primary analysis results from the phase 3 COMMANDS study.
Luspatercept provides a new standard of care for erythropoiesis-stimulating agent-naïve patients with transfusion-dependent, lower-risk myelodysplastic syndromes, determined primary analysis results from the phase 3 COMMANDS study.
Luspatercept provides a new...
10/02/2024
Oncology
News
Initial Low Dose Lenalidomide Over 2 Years Improves Treatment Response Among Non-Transfusion-Dependent Patients With Low-Risk MDS
09/19/2024
Amber Denham
An initial treatment of low doses of lenalidomide distributed across 2 years was shown to safely prolong the time to transfusion-dependency and improve responses among non-transfusion-dependent patients with low-risk, del(5q) myelodysplastic...
An initial treatment of low doses of lenalidomide distributed across 2 years was shown to safely prolong the time to transfusion-dependency and improve responses among non-transfusion-dependent patients with low-risk, del(5q) myelodysplastic...
An initial treatment of low...
09/19/2024
Oncology
News
FDA Grants Approval to Imetelstat for Patients With Low to Intermediate-1 Risk Myelodysplastic Syndrome With Transfusion-Dependent Anemia
06/21/2024
The FDA granted approval to imetelstat for patients with low to intermediate-1 risk MDS with transfusion-dependent anemia requiring 4 or more red blood cell transfusion units over 8 weeks, who cannot derive benefit from...
The FDA granted approval to imetelstat for patients with low to intermediate-1 risk MDS with transfusion-dependent anemia requiring 4 or more red blood cell transfusion units over 8 weeks, who cannot derive benefit from...
The FDA granted approval to...
06/21/2024
Oncology
News
Azacitidine Maintenance Demonstrates Lower Disease Progression Rate Among Patients With High-Risk FLT3-Negative AML/MDS
03/05/2024

Amber Denham

Amber Denham
According to a retrospective analysis, azacitidine maintenance is associated with a lower progression rate in patients with high-risk FLT3-negative acute myeloid leukemia or myelodysplastic syndrome.
According to a retrospective analysis, azacitidine maintenance is associated with a lower progression rate in patients with high-risk FLT3-negative acute myeloid leukemia or myelodysplastic syndrome.
According to a retrospective...
03/05/2024
Oncology
News
Oral Decitabine Cedazuridine Safe, Effective Alternative to Intravenous Decitabine for Patients With MDS or CML
02/21/2024
Amber Denham
Oral decitabine cedazuridine demonstrates safety and efficacy as an alternative to intravenous decitabine treatment among patients with myelodysplastic syndromes or chronic myelomonocytic leukemia, according to phase 3 study results.
Oral decitabine cedazuridine demonstrates safety and efficacy as an alternative to intravenous decitabine treatment among patients with myelodysplastic syndromes or chronic myelomonocytic leukemia, according to phase 3 study results.
Oral decitabine cedazuridine...
02/21/2024
Oncology
News
Assessment of Individualized MRD With NGS, ddPCR Effective for Early Detection of MDS Relapse
02/09/2024
Amber Denham
Evaluating individualized measurable residual disease with next-generation sequencing and droplet digital polymerase chain reaction is feasible and can be used for early detection of relapse among patients with myelodysplastic syndrome,...
Evaluating individualized measurable residual disease with next-generation sequencing and droplet digital polymerase chain reaction is feasible and can be used for early detection of relapse among patients with myelodysplastic syndrome,...
Evaluating individualized...
02/09/2024
Oncology
News
Efficacy of Azacitidine Among Treatment-Naive Patients With Higher-Risk Myelodysplastic Syndromes
01/31/2024
Amber Denham
Azacitidine demonstrated low complete remission rates and low median overall survival as a frontline therapy for patients with high-risk myelodysplastic syndromes, according to a retrospective study.
Azacitidine demonstrated low complete remission rates and low median overall survival as a frontline therapy for patients with high-risk myelodysplastic syndromes, according to a retrospective study.
Azacitidine demonstrated low...
01/31/2024
Oncology
News
Sabatolimab Plus Hypomethylating Agents as Frontline Therapy for Patients With Higher-Risk MDS
01/11/2024
Amber Denham
A phase 2 trial determined that the addition of sabatolimab to hypomethylating agents showed manageable safety, but did not result in a significant improvement in complete response rates or progression-free survival for untreated patients...
A phase 2 trial determined that the addition of sabatolimab to hypomethylating agents showed manageable safety, but did not result in a significant improvement in complete response rates or progression-free survival for untreated patients...
A phase 2 trial determined that...
01/11/2024
Oncology
News
Sintilimab Plus Anlotinib Demonstrates Promise in Relapsed/Refractory Small Cell Lung Cancer
04/02/2026
Stephanie Holland
Results from a phase 2 trial suggest that sintilimab plus anlotinib demonstrates encouraging efficacy with manageable safety among patients with relapsed/refractory small cell lung cancer (SCLC) who have a short chemotherapy-free...
Results from a phase 2 trial suggest that sintilimab plus anlotinib demonstrates encouraging efficacy with manageable safety among patients with relapsed/refractory small cell lung cancer (SCLC) who have a short chemotherapy-free...
Results from a phase 2 trial...
04/02/2026
Oncology
News
Adebrelimab Plus Chemotherapy Maintains Long-Term Survival Benefit in ES-SCLC
04/02/2026
Stephanie Holland
Updated results from the phase 3 CAPSTONE-1 trial demonstrate that adebrelimab plus chemotherapy continues to provide durable survival benefit in patients with extensive-stage small cell lung cancer.
Updated results from the phase 3 CAPSTONE-1 trial demonstrate that adebrelimab plus chemotherapy continues to provide durable survival benefit in patients with extensive-stage small cell lung cancer.
Updated results from the phase 3...
04/02/2026
Oncology
News
Lurbinectedin Plus Atezolizumab Delays Subsequent Therapy and Maintains Survival Benefit in ES-SCLC
04/02/2026
Stephanie Holland
Exploratory results from the phase 3 IMforte trial suggest that first-line treatment with lurbinectedin plus atezolizumab delays subsequent therapy and maintains overall survival benefit in patients with extensive-stage small cell lung cancer.
Exploratory results from the phase 3 IMforte trial suggest that first-line treatment with lurbinectedin plus atezolizumab delays subsequent therapy and maintains overall survival benefit in patients with extensive-stage small cell lung cancer.
Exploratory results from the...
04/02/2026
Oncology
FDA Approval
FDA Approves Brexucabtagene Autoleucel for R/R Mantle Cell Lymphoma
04/02/2026
Stephanie Holland
Based on results from the phase 2 ZUMA-2 study, the FDA approved brexucabtagene autoleucel for adult patients with relapsed/refractory mantle cell lymphoma, including those who are BTK inhibitor–naïve.
Based on results from the phase 2 ZUMA-2 study, the FDA approved brexucabtagene autoleucel for adult patients with relapsed/refractory mantle cell lymphoma, including those who are BTK inhibitor–naïve.
Based on results from the phase...
04/02/2026
Oncology
News
Consolidation Serplulimab Following Hypo-cCRT Improves Outcomes in Limited-Stage Small Cell Lung Cancer
04/02/2026
Emily Estrada
Updated results from the phase 2 ASTRUM-LC01 trial demonstrate that following concurrent Hypo-cCRT with consolidation serplulimab improves survival with manageable safety in limited-stage small cell lung cancer.
Updated results from the phase 2 ASTRUM-LC01 trial demonstrate that following concurrent Hypo-cCRT with consolidation serplulimab improves survival with manageable safety in limited-stage small cell lung cancer.
Updated results from the phase 2...
04/02/2026
Oncology
News
Izalontamab Brengitecan Plus Serplulimab Demonstrates Strong Promise in Treatment-Naïve ES-SCLC
04/01/2026
Emily Estrada
According to results from the phase 2 BL-B01D1-204-01 study, izalontamab brengitecan plus serplulimab demonstrated encouraging efficacy with manageable safety in treatment- extensive-stage small cell lung cancer.
According to results from the phase 2 BL-B01D1-204-01 study, izalontamab brengitecan plus serplulimab demonstrated encouraging efficacy with manageable safety in treatment- extensive-stage small cell lung cancer.
According to results from the...
04/01/2026
Oncology
News
Transdermal Estradiol Noninferior to LHRH Agonists in Locally Advanced Prostate Cancer
04/01/2026
Stephanie Holland
Results from a phase 3 study demonstrated that transdermal estradiol was noninferior to luteinizing hormone-releasing hormone agonists for survival outcomes among patients with locally advanced prostate cancer.
Results from a phase 3 study demonstrated that transdermal estradiol was noninferior to luteinizing hormone-releasing hormone agonists for survival outcomes among patients with locally advanced prostate cancer.
Results from a phase 3 study...
04/01/2026
Oncology
News
Etrumadenant-Based Chemoimmunotherapy Improves Survival in Metastatic Colorectal Cancer
04/01/2026
Emily Estrada
Results from the phase 2 ARC-9 study, demonstrate that etrumadenant plus zimberelimab, mFOLFOX-6, and bevacizumab significantly improves survival in heavily pretreated patients with metastatic colorectal cancer.
Results from the phase 2 ARC-9 study, demonstrate that etrumadenant plus zimberelimab, mFOLFOX-6, and bevacizumab significantly improves survival in heavily pretreated patients with metastatic colorectal cancer.
Results from the phase 2 ARC-9...
04/01/2026
Oncology
News
Distinct Immune Microenvironment Associated With Long-Term Survival in High-Grade Glioma
03/31/2026
Emily Estrada
Results from a translational analysis suggest that long-term survival in patients with high-grade glioma is associated with a distinct immune microenvironment characterized by enhanced NK cell activity and microglial activation.
Results from a translational analysis suggest that long-term survival in patients with high-grade glioma is associated with a distinct immune microenvironment characterized by enhanced NK cell activity and microglial activation.
Results from a translational...
03/31/2026
Oncology
News
Ruxolitinib Plus Venetoclax Demonstrates Safe but Limited Clinical Activity in Relapsed/Refractory AML
03/31/2026
Emily Estrada
Results from a multicenter, phase 1 trial demonstrated that ruxolitinib plus venetoclax is well tolerated but shows modest clinical activity in heavily pretreated relapsed/refractory acute myeloid leukemia.
Results from a multicenter, phase 1 trial demonstrated that ruxolitinib plus venetoclax is well tolerated but shows modest clinical activity in heavily pretreated relapsed/refractory acute myeloid leukemia.
Results from a multicenter,...
03/31/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use